Alnylam Pharmaceuticals ALNY · USD
Health Care · Biotechnology · US listing · 🇺🇸 United States
Nasdaq-100
156.61
+0.43%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Alnylam Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Alnylam Pharmaceuticals is based in Cambridge, Massachusetts. Its shares trade on Nasdaq under the ticker ALNY. It is a member of the Nasdaq-100. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $3.71bn and net income of $313.7m. At that date it held total assets of $4.97bn and shareholders' equity of $789.2m.
Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. By harnessing the RNAi pathway, we have pioneered a new class of innovative medicines, known as RNAi therapeutics. RNAi therapeutics are comprised of small interfering RNA, or siRNA, that function upstream of conventional medicines by potently silencing messenger RNA, or mRNA, that encode for proteins implicated in the cause or pathway of disease, thus preventing them from being made. We believe this is a revolutionary approach with the potential to transform the care of patients across a broad range of disease areas and indications. To date, our efforts to advance this revolutionary approach have yielded the approval of six first-in-class RNAi-based medicines: AMVUTTRA® (vutrisiran), ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), Leqvio® (inclisiran) and Qfitlia® (fitusiran).
Quoted from its 10-K, filed 12 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 May 2004
- Employees
- 2,500
- Website
- alnylam.com ↗
- Head office
- 675 WEST KENDALL STREET, CAMBRIDGE, MA, 02142
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Amy SchulmanIndependent Chairman of the Board$558,790
- Dr. Yvonne GreenstreetChief Executive Officer, Director, since 2016$11.5m
- Mr. Jeffrey PoultonChief Financial Officer, Executive Vice President$3.8m
- Dr. Kevin FitzgeraldExecutive Vice President, Chief Scientific Officer, Head - Early Research and Early Development$2.7m
- Mr. Robert HessleinExecutive Vice President, Chief Legal Officer, Secretary
- Dr. Pushkal GargExecutive Vice President, Chief Research and Development Officer, since 2025$2.9m
- Mr. Michael BonneyChief Compliance Officer, Director, since 2014$458,790
- Mr. Tolga TangulerChief Commercial Officer$2.8m
- Dr. Dennis AusielloIndependent Director$478,790
- Ms. Carolyn BertozziIndependent Director$438,790
- Dr. Olivier BrandicourtIndependent Director$481,290
- Dr. Margaret HamburgIndependent Director$468,790
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 61
- Environment
- 59
- Social
- 94
- Governance
- 30
- Direct emissions (scope 1)
- 3,832 t
- Energy emissions (scope 2)
- 9,677 t
- Value chain emissions (scope 3)
- 160,413 t
- Women in the workforce
- 56%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Alnylam Pharmaceuticals Inc has several strengths that contribute to its competitive advantage in the market:
Weaknesses
- Despite its strengths, Alnylam Pharmaceuticals Inc also faces certain weaknesses that may hinder its growth:
Opportunities
- Alnylam Pharmaceuticals Inc can capitalize on the following opportunities to enhance its position in the industry:
Threats
- Alnylam Pharmaceuticals Inc faces the following threats that could impact its business and market position:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.